 I. To identify the maximum tolerated dose MTDrecommended phase 2 dose RP2D for a regimen combining WEE1 inhibitor AZD1775 AZD1775 with belinostat in patients with refractoryrelapsed acute myeloid leukemia AML, chronic myeloid leukemia in blast crisis CML-BC, or intermediate-2 or high-risk myelodysplastic syndrome MDS, and selected previously untreated poor-prognosis patients with AML. 